Announcements Trials
Browse Landscape

Status

Active not recruiting 2Recruiting 1Completed 1Available 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urologic Neoplasms 1Urinary Bladder Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

3-Iodobenzylguanidine 4tempol 2balstilimab 2zolbetuximab 1zipalertinib 1venetoclax 1ulixertinib 1tisagenlecleucel 1tipifarnib 1tebentafusp 1talazoparib 1sodium thiosulfate 1selinexor 1ruxolitinib 1ribociclib 1osunprotafib 1nirogacestat 1mirdametinib 1mifamurtide 1lifileucel 1leronlimab 1idecabtagene vicleucel 1gedatolisib 1fluorodopa F 18 1fluorocholine 1epigallocatechin gallate 1ensartinib 1dodecyl maltoside 1carbon-11 methionine 1burosumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Available × dodecyl maltoside × Clear all
NCT06443944 2026-04-14

An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG

CG Oncology, Inc.

Available
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡